[1] Morrison SJ,Spradling AC.Stem Cells and Niches: Mechanisms That Promote Stem Cell Maintenance throughout Life.Cell.2008;132(4):598-611.[2] Kovacic B,Rosner M,Schipany K,et al.Clinical impact of studying epithelial–mesenchymal plasticity in pluripotent stem cells.Eur J Clin Invest.2015;45(4):415-422.[3] Donnenberg VS,Donnenberg AD.Stem cell state and the epithelial to mesenchymal transition: Implications for cancer therapy.J Clin Pharmacol.2015;55(6):603-619.[4] 冯年花,谢安,娄远蕾,等.人诱导性多能干细胞的培养及鉴定[J].实验与检验医学,2010,28(1):6-8.[5] Baselga J,Cortés J,Kim SB,et al.Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.N Engl J Med.2012;366(2):109-119. [6] Aceto N,Bardia A,Miyamoto DT,et al.Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell.2014;158(5):1110-1122.[7] Friedl P.Prespecification and plasticity: shifting mechanisms of cell migration.Curr Opin Cell Biol.2004;16(1):14-23.[8] 林媛媛,娄远蕾,梁昌达,等.人诱导多能干细胞自然分化过程中EMT变化研究[J].实验与检验医学,2013,31(6):518-520.[9] Radisky DC.Epithelial-mesenchymal transition.J Cell Sci. 2005;118(Pt 19): 4325-4326.[10] Easwaran H,Tsai HC,Baylin SB.Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance.Mol Cell.2014;54(5):716-727. [11] Mlecnik B,Bindea G,Angell HK,et al.Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity. 2016; 44(3):698.[12] Smith BN,Bhowmick NA.Role of EMT in Metastasis and Therapy Resistance.J Clin Med. 2016;5(2):17.[13] De Craene B,Berx G.Regulatory networks defining EMT during cancer initiation and progression.Nat Rev Cancer. 2013;13(2):97-110.[14] Lee Y,Jung WH,Koo JS.Adipocytes can induce epithelial-mesenchymal transition in breast cancer cells.Breast Cancer.2015;153(2):323-335.[15] Li X,Pei D,Zheng H.Transitions between epithelial and mesenchymal states during cell fate conversions.Protein Cell.2014;5(8):580-591.[16] Dong L,Ni J,Hu W,et al.Upregulation of Long Non-Coding RNA PlncRNA-1 Promotes Metastasis and Induces Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.Cell Physiol Biochem.2016;38(2):836-846. [17] Okita K,Yamanaka S.Induced pluripotent stem cells: opportunities and challenges. Regenerative Med.2015; 5(4): 483-484.[18] Eastham AM,Spencer H,Soncin F,et al. Epithelial- mesenchymal transition events during human embryonic stem cell differentiation.Cancer Res.2007;67(23):11254-11262.[19] Li D,Zhou J,Chowdhury F,et al.Role of mechanical factors in fate decisions of stem cells.Regen Med.2016;6(2):229-240. [20] Abell AN,Johnson GL.Implications of Mesenchymal Cells in Cancer Stem Cell Populations: Relevance to EMT.Curr PathobiolRep.2014;2(1):21-26.[21] 张秀红,杨增明.上皮细胞-间充质细胞转换(EMT)在癌症转移、胚胎发育及哺乳动物雌性生殖过程中的作用机制[J].生物化学与生物物理进展,2012,39(4):307-313.[22] Celià-Terrassa T,Meca-Cortés O,Mateo F,et al. Epithelial-mesenchymal transition can suppress major attributes of, human epithelial tumor-initiating cells.J Clin Invest.2012;122(5):1849-68.[23] Makki J,Myint O,Wynn AA,et al.Expression Distribution of Cancer Stem Cells, Epithelial to Mesenchymal Transition, and Telomerase Activity in Breast Cancer and Their Association with Clinicopathologic Characteristics.Clin Med Insights Pathol.2015;8:1-16.[24] Mani SA,Guo W,Liao MJ,et al.The epithelial-mesenchymal transition generates cells with properties of stem cells.Cell. 2008;133(4):704. [25] Li X,Kong X,Huo Q,et al.Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition.Cancer Sci.2011; 102(6):1151-1157. [26] Davis FM,Stewart TA,Thompson EW,et al.Targeting EMT in cancer: opportunities for pharmacological intervention.Trends Pharmacol Sci.2014;35(9):479-488.[27] Singh A,Settleman J.EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.Oncogene.2010;29(34):4741-4751. [28] Na Y,Kaul SC,Ryu J,et al.Stress chaperone mortalin contributes to epithelial-mesenchymal transition and cancer metastasis. Cancer Res.2016.pii: canres.2704.2015. [Epub ahead of print][29] Medici D,Muñoz-Cánoves P,Yang PC,et al.Mesenchymal Transitions in Development and Disease.Stem Cells Int.2016;2016:1-2. [30] Greening DW,Gopal SK,Mathias RA,et al.Emerging roles of exosomes during epithelial-mesenchymal transition and cancer progression.Semin Cell Dev Biol.2015;40:60.[31] Thiery JP.Epithelial- mesenchymal transitions in tumour progression.Nat Rev Cancer.2002;2(6):442-454.[32] Voutsadakis IA.Epithelial-Mesenchymal Transition (EMT) and Regulation of EMT Factors by Steroid Nuclear Receptors in Breast Cancer: A Review and in Silico Investigation.J Clin Med.2016;5(1).pii: E11.doi: 10.3390/jcm5010011.[33] Hu QP,Kuang JY,Yang QK,et al. Beyond a tumor suppressor: Soluble E-cadherin promotes the progression of cancer.Int J Cancer.2016;138(12):2804-2812.[34] Saliminejad K,Edalatkhah H,Kamali K,et al.Association of common variations of the E-cadherin with endometriosis. Gynecol Endocrinol.2015;56(234):1-4. [35] Cheng CW, Wu PE,Yu JC,et al.Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two- hit hypothesis of tumor suppressor gene. Oncogene. 2001; 20(29):3814-3823.[36] Tiwari N,Gheldof A,Tatari M,et al.EMT as the ultimate survival mechanism of cancer cells.Semin Cancer Biol.2012;22(22): 194-207.[37] Qi L,Song W,Wang W,et al.Suppression of epithelial- mesenchymal transition in hepatocellular carcinoma cells by Krüppel-like factor 4.Oncotarget.2016; 7(20):29749-29760.[38] Nickel A,Stadler SC.Role of epigenetic mechanisms in epithelial-to-mesenchymal transition of breast cancer cells.Transl Res.2015;165(1):126-42.[39] 张华东,黄勇,李宏伟,等.上皮-间质转化研究进展[J].中国现代医学杂志,2011,21(31):3907-3911.[40] Gonzalez DM,Medici D.Signaling mechanisms of the epithelial-mesenchymal transition.Sci Signal.2014;7(344):re8. [41] Zavadil JBÖttinger EP.TGF- beta and epithelial- to- mesenchymal transitions.Oncogene.2005;24(37):5764-5774.[42] Wang T,Li Y,Wang W,et al.Twist2, the key Twist isoform related to prognosis, promotes invasion of cervical cancer by inducing epithelial-mesenchymal transition and blocking senescence. Hum Pathol.2014;45(9):1839.[43] Xu J,Lamouille S,Derynck R.TGF-b-induced epithelial to mesenchymal transition.Cell Res.2009;19(2):156-172.[44] 王菲菲,单保恩.TGF-β1诱导乳腺癌细胞向肿瘤干细胞转化的EMT机制研究[C].海峡两岸肿瘤学术会议,2014.[45] Zhao JJ,Lin J,Zhu D,et al.miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 Pathway.Cancer Res. 2014; 74(6):1801-1813. [46] Xiao H,Zhang J,Xu Z,et al.Metformin is a novel suppressor for transforming growth factor(TGF)β1.Sci Rep.2016;6:28597.[47] Zaravinos A.The Regulatory Role of MicroRNAs in EMT and Cancer.J Oncol.2015; 2015:865-816.[48] Kodaka M,Hata Y.The mammalian Hippo pathway: regulation and function of YAP1 and TAZ. Cell MolLife Sci.2015;72(2): 285-306.[49] Meng Z,Moroishi T,Guan KL.Mechanisms of Hippo pathway regulation. Genes & Development, 2016;30(1):1-17.[50] Kim M,Kim T,Johnson RL,et al.Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.Cell Rep.2015;5(2):270-282. |